Insulet Corporation
Nov 2, 2016
PDF

New Study Shows Majority of Omnipod® Insulin Management System Users Report Significant Clinical and Quality of Life Benefits

Data Published in Diabetes Technology & Therapeutics Demonstrates Improved A1c Levels, Patients' Well-Being, and Perceived Control over Diabetes

BILLERICA, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced the online publication of new data in Diabetes Technology & Therapeutics1 that continue to validate the substantial quality of life benefits of the Omnipod System. In this study, more than 1,200 current adult Omnipod users with type 1 diabetes completed an online questionnaire to examine perceived changes in quality of life and glycemic control. The majority reported positive changes in perceived control over their diabetes (72.5%), diabetes distress (69.6%), overall well-being (53.5%) and hypoglycemic safety (50.6%) since starting use of Omnipod (P < 0.001).

The majority of patients also reported significant improvement in glycemic control (64.2%) since starting on the Omnipod System, with more than one-third (35.2%) describing a decrease in severe hypoglycemic episodes. Approximately 60% of patients previously used multiple daily injections and approximately 40% were previously treated with traditional tubed pumps.

"While past evidence has suggested that all insulin pumps may contribute to improved quality of life for people with type 1 diabetes, there have been few studies until now that have examined the quality of life impact of the newer, more differentiated systems like Omnipod," said William Polonsky, PhD, principal investigator of the study and associate clinical professor in psychiatry at the University of California San Diego. "These findings provide insight into the Omnipod user experience and demonstrate that users' trust in the Omnipod System and reported improvements in glycemic control are significant factors that can enhance the individual's quality of life."

"The results of this study reinforce Omnipod's differentiated design and the freedom and improved quality of life it offers," said Patrick Sullivan, Chairman and Chief Executive Officer. "The body of evidence supporting Omnipod's unique advantages continues to grow and is driving increased awareness so more people can benefit from this remarkable technology."

About the Omnipod Insulin Management System:

The Omnipod Insulin Management System is an innovative continuous insulin delivery system that provides all the proven benefits of continuous subcutaneous insulin infusion (CSII) therapy in a way no conventional insulin pump can. The Omnipod System's innovative design and features allows people living with diabetes to live their life—and manage their diabetes—with unprecedented freedom, comfort, convenience, and ease. The Omnipod System consists of two components: (i) a Pod that stores and delivers insulin; and (ii) a Personal Diabetes Manager (PDM) that wirelessly programs the user's personalized insulin delivery, calculates suggested doses and insulin on board, and has a convenient, built-in blood glucose meter. The small, light-weight Pod can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back and, because it is waterproof (IPX8), there is no need to remove when showering, swimming or performing other activities. This means that Omnipod can provide up to three days of non-stop insulin delivery, without the need to disconnect a tube set or manually inject insulin. The Pod and PDM communicate wirelessly to offer precise, personalized and continuous insulin delivery with customizable basal and bolus delivery options, as well as important safety checks. The Pod's auto-cannula insertion is quick, simple, and virtually pain-free. Users never have to handle a needle. The user simply pushes a button on the PDM and the Pod's automated insertion system inserts the cannula beneath the skin and begins delivering insulin according to the user's programmed basal rate.

The Omnipod System is the world's first commercially available tubeless insulin delivery system that allows users to live untethered by tubing and without the stress and anxiety of multiple daily injections. By breaking down the barriers to insulin pump therapy, the Omnipod System offers freedom for users to live life on their own terms and with the ease of use they deserve.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its Omnipod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The Omnipod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to tailor the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.

Forward-Looking Statement:

This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 29, 2016 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

1 Polonsky WH, Hessler D, Layne JE, Zisser H. Impact of the Omnipod® Insulin Management System on Quality of Life: A Survey of Current Users. Diabetes Technology & Therapeutics. Oct 2016: 664-670.

Insulet Corporation
Deborah R. Gordon, 978-600-7717
Vice President, Investor Relations and Corporate Communications
dgordon@insulet.com

Source: Insulet Corporation

News Provided by Acquire Media